Investigation of conjunctivitis adenovirus spread in human eyes by using bifurcation tool and numerical treatment approach

Abstract

Abstract In order to investigate the dynamics of the system, a mathematical model must be created to comprehend the dynamics of various prevalent diseases worldwide. The purpose of this investigation is to explore the early identification and treatment of conjunctivitis adenovirus by introducing vaccination methods for asymptomatic individuals. A mathematical model is constructed with the aim of strengthening the immune system. The ABC operator is then utilized to convert the model into a fractionally ordered one. The developed system is analyzed with analytical solutions by employing Sumudu transforms, including convergence analysis. The boundedness and uniqueness of the model are investigated using Banach space, which are key properties of such epidemic models. The uniqueness of the system is confirmed to ensure it has a unique solution. The stability of the newly constructed SEVIR system is investigated both qualitatively and statistically, and the system’s flip bifurcation has been verified. The developed system is examined through a Lyapunov function-based local and global stability study. The solution to the system is found using the Atangana-Toufik technique, a sophisticated method for reliable bounded solutions, employing various fractional values. Error analysis has also been conducted for the scheme. Simulations have been carried out to observe the real behavior and effects of the conjunctivitis virus, confirming that individuals with a strong immune response can recover without medication during the acute stage of infection. This helps to understand the real situation regarding the control of conjunctivitis adenovirus after early detection and treatment by introducing vaccination measures due to the strong immune response of the patients. Such investigations are useful for understanding the spread of the disease and for developing control strategies based on the justified outcomes.